Nycomed joined Takeda on September 30, 2011
Here you will find relevant information related to the acquisition of Nycomed by Takeda.
The addition of Nycomed is a significant step forward in Takeda’s sustainable growth strategy, enabling us to expand and increase our presence in newly penetrated and emerging markets.
The New Takeda will operate in more than 70 countries around the world, including the United States, Japan, Asia and Europe, with particular strength in the fast-growing emerging markets of Russia, Brazil, China and India. The combination with Nycomed creates a truly global business.
Our partnerships are at the core of our business strategy. We are partners with the most successful and innovative healthcare companies in the world.
A truly global R&D structure in Japan, Europe, the United States and the rest of the world reflects our balanced geographical footprint and is matched by our dedication to researching and developing medicines that make a real difference to patients’ lives.
Meeting the Needs of Patients
The combined company will have an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management, as well as having a well-balanced presence in pharmaceutical markets in Japan, North America, Europe and emerging markets.
Additional information about Takeda is available through its corporate website, www.takeda.com.
70+ Countries where Takeda has a presence
Balanced in the critical pharma markets of Japan, Asia, the US and Europe, as well as emerging markets
12th Largest globally
18th in European markets;
14th in BRICS
#1 Top share in the largest and most admired
Japan's largest and most admired pharmaceutical company
30% Nycomed annual growth in emerging markets in 2010
Emerging Markets contributed to 50% of global pharma market growth during 2005-2010